An engineered messenger RNA includes a protein-coding message and surrounding features that affect how it is used. Those features are part of the construct being tested.
The cap, untranslated regions, coding sequence and poly(A) tail are distinct parts of a messenger RNA construct. A primary dendritic-cell study changed untranslated-region and poly(A)-tail features and measured RNA stability, protein production, peptide display and T-cell stimulation separately. Another experimental study separated effects of codon usage and RNA structure on protein expression. Construct design therefore includes more than the intended amino-acid sequence. A design that improves one measured step in one system does not establish optimal immune effects or clinical efficacy in another.
Start-codon context was tested by single-base substitutions around the AUG initiator in a cloned preproinsulin gene, where the best sequence identified changed proinsulin yield over a 20-fold range (Kozak). The interaction of the cap and the poly(A) tail was tested with luciferase mRNAs delivered by electroporation into tobacco protoplasts, Chinese hamster ovary cells and yeast, where the tail's effect depended on the cap (Gallie). A textbook describes the 5' cap, 5' and 3' untranslated regions that regulate translation initiation and mRNA stability, a poly-A tail of about 200 A residues added by poly-A polymerase to cellular mRNA, and a ribosome that moves from the cap to the AUG, with Kozak's rules describing the sequence around it (OpenStax Biology 2e). The cellular tail length is not a rule for engineered constructs: one dendritic-cell study found that a 120-nucleotide tail, an unmasked tail end and two 3' untranslated regions each improved stability and translation, and it measured transcript amount by RT-PCR, protein by eGFP, peptide-MHC density and T-cell stimulation separately (Holtkamp and colleagues), so a doubled reporter signal after a 3' change is one measurement, not a different antigen or a clinical benefit. These are tested constructs and cell systems, not one best sequence for a clinical product.
Shares Modified nucleosides in messenger RNA, In vitro transcription for RNA products, Immune measurements and product evidence.
Shares In vitro transcription for RNA products, mRNA and lipid nanoparticle manufacturing, Immune measurements and product evidence.
Shares Multi-epitope constructs and antigen processing, Immune measurements and product evidence.
Shares Delivery targets and therapeutic targets, Immune measurements and product evidence.
Shares In vitro transcription for RNA products, mRNA and lipid nanoparticle manufacturing.
Shares Multi-epitope constructs and antigen processing, Immune measurements and product evidence.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/